Journals / Üroonkoloji Bülteni / 2021 / Cilt: 20 - Sayı: 2

Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity

Yaşlılarda Prostat Kanseri Tedavisine Yaklaşım Yüksek Komorbiditesi Olan Hastalar

Pages
73–82
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For patients who are frail but have treatable disease, standard treatment is recommended after correction or improvement of comorbidities.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The incidence of prostate cancer increases with age, and elderly patients often have other accompanying diseases.
📊
Key Findings & Data:The most important clinical prediction for deciding on curative treatment in localized prostate cancer treatment is the 10-year survival status of the patient.
💡
Conclusion & Impact:For patients who are frail but have treatable disease, standard treatment is recommended after correction or improvement of comorbidities.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The incidence of prostate cancer increases with age, and elderly patients often have other accompanying diseases. The most important clinical prediction for deciding on curative treatment in localized prostate cancer treatment is the 10-year survival status of the patient. In advanced prostate cancers, treatment is usually decided according to the comorbidity and age of the patients. Guidelines and consensus reports recommend that patients’ general health status should be determined by validated health status screening forms in deciding on treatment for prostate cancer in elderly patients. After evaluating the health status, the treatment options recommended by the guidelines should be presented to the patients according to the risk group of the patient and the treatability of the existing diseases, regardless of their age. Patients who are found to be healthy as a result of the evaluation should be included in the standard treatment applied to non-elderly patients. For patients who are frail but have treatable disease, standard treatment is recommended after correction or improvement of comorbidities. Supportive treatment and adapted treatment options should be offered to the patients who are in a frail state.

Özet

Prostat kanseri insidansı yaşla birlikte artar ve yaşlı hastalarda sıklıkla eşlik eden başka hastalıklar bulunur. için en önemli klinik tahmin Lokalize prostat kanseri tedavisinde küratif tedaviye karar vermek hastanın 10 yıllık sağkalım durumudur. İlerlemiş prostat kanserlerinde tedavi genellikle hastaların komorbiditesine ve yaşına göre karar verilir. Kılavuzlar ve fikir birliği raporları, hastaların genel sağlık durumunun yaşlı hastalarda prostat kanseri tedavisine karar verirken geçerli sağlık durumu tarama formları ile belirlenmelidir. Sağlık durumunu değerlendirdikten sonra, Hastanın risk grubuna ve tedavi edilebilirliğine göre kılavuzların önerdiği tedavi seçenekleri hastalara sunulmalıdır. Yaşlarına bakılmaksızın mevcut hastalıklar. Değerlendirme sonucunda sağlıklı bulunan hastalar uygulanan standart tedaviye dahil edilmelidir. yaşlı olmayan hastalar. Kırılgan ancak tedavi edilebilir hastalığı olan hastalar için, komorbiditelerin düzeltilmesi veya iyileştirilmesinden sonra standart tedavi önerilir. Kırılgan durumdaki hastalara destekleyici tedavi ve uyarlanmış tedavi seçenekleri sunulmalıdır.

🔖

Cite This Article

TAVUKÇU, H. H., KAPLAN, M. (2022). Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. Üroonkoloji Bülteni, Cilt: 20 - Sayı: 2, 73–82. https://ajindex.com/articles/645737

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. National Cancer Institute. SEERCancer Stat Facts: prostate cancer. 2018. Available from: https//seercancergouv/statfacts/html/ prosthtml2018. 2018
  2. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758-2765
  3. Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 2015;51:1164-1187
  4. Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 2019;116:116-136
  5. Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011;107:576-584
  6. Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29:1335
  7. Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010;73:68-91
  8. Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010;106:462-469
  9. Droz JP, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol 2017;72:521-531
  10. Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014;15:e404-e414. doi: 10.1016/S1470-2045(14)70018-X
  11. Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One 2014;9:e115060. doi: 10.1371/journal. pone.0115060
  12. Droz JP, Boyle H, Albrand G, et al. Role of geriatric oncologists in optimizing care of urological oncology patients. Eur Urol Focus 2017;3:385-394
  13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655
  14. Wedding U, Kodding D, Pientka L, et al. Physicians’ judgement and comprehensive geriatric assessment (CGA) select